GRI Berita Valas

GRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%

Biotechnology company GRI Bio, Inc. (GRI) announced Monday that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF.

RTTNews | 614 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.15956	GBPUSD	1.32834	AUDUSD	0.64735
USDJPY	147.381	USDCAD	1.37779	USDCHF	0.8035

Advertisement

GRI Berita Valas

GRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%